Skip to evidence report

IPSC.mesodermal_primed: Studies — page 11

How association tiers are defined — cell–trait and gene–trait

SCREATE tier definitions supplied by the atlas curator. This methods note explains the prepared classifications; it does not recompute or change any report scores or tiers.

Cell–trait tiers

Cell–trait links
Identify cell types whose regulatory activity is associated with a trait’s genetic signal.
Required for Specific or Relevant
The ICE-CREAM score derived from the mean metacell Z score must be ≥ 5.39, with BOTH nominal and adjusted ICE-CREAM P values ≤ 0.05.
Specific (Tier 1)
Also meets all cell-set enrichment analysis (CSEA) criteria in at least one tested comparison: nominal P ≤ 0.05 AND adjusted P ≤ 0.05 AND normalized enrichment score (NES) ≥ 1, all in that comparison. This indicates that trait-associated activity is concentrated in this cell type relative to the tested background.
Relevant (Tier 2)
Meets the ICE-CREAM requirements but not the additional CSEA criteria. The cell type may share trait-associated activity with other cell types.
Interpretation and report values
CSEA is cell-set enrichment analysis, analogous to gene-set enrichment analysis but using sets of cells along a ranked list of ICE-CREAM scores. The eligibility score derived from the mean metacell Z score is not the displayed mean IC score. Do not infer a tier from the displayed mean, its descriptive Significance column, or a single CSEA summary value. Reports preserve prepared tiers; Other means an available association outside Specific/Relevant, and unavailable is not zero or proof of biological irrelevance.
Meta traits and individual traits
Use the prepared tier for the exact meta trait or individual trait. A meta trait’s Best child CSEA FDR is the lowest available child FDR, not a combined or meta-trait significance test. Its displayed mean child NES is descriptive, not a new CSEA test. These summaries must not be used to reconstruct or override the meta-trait tier.

Gene–trait priorities (variant–tCRE–gene evidence)

Variant–tCRE–gene links
Candidate variants connect to genes through overlapping promoters or distal transcribed cis-regulatory elements (tCREs) linked to gene promoters by the Activity-by-Contact (ABC) model.
Required genetic support
The variant belongs to a purity-passing SuSiE credible set OR qualifies for Borzoi rescue. Borzoi rescue requires BOTH a variant-causality score ≥ 0.3 AND linkage disequilibrium with the lead variant of r² ≥ 0.2.
Required cellular support
The overlapping promoter has positive tCRE activity OR the distal element has a passing cell-specific ABC link to the gene, in a Specific or Relevant cell subtype (L1S) or fine-grained state (L2). BOTH genetic and cellular support are required for High or Medium priority.
High priority
Among records meeting both minimum requirements, High requires a genetic score ≥ 0.5 AND a Layer 1 correlation > 0.3 between tCRE activity and the trait’s cellular profile across cell subtypes.
Medium priority
Meets both minimum requirements but not one or both additional High thresholds. The genetic score is the higher of the SuSiE posterior inclusion probability (PIP) and the Borzoi variant-causality score.
Same-record evidence and aggregation
Each priority requires genetic and cellular evidence supporting the SAME variant–tCRE–gene record. Do not combine thresholds or evidence from different records to create a qualifying link. A gene receives the highest priority observed among its supporting records. A tCRE summary uses supporting records for that exact tCRE, not every trait of its linked genes. Separately displayed aggregate scores do not relax the same-record rule.
Limits of interpretation
A priority is candidate-association evidence, not proof of a causal variant, causal gene, causal cell type or treatment efficacy. Missing evidence is unavailable, not zero. MAGMA −log10(P), displayed credibility scores, cellular-context scores and G/C tier codes must not be substituted for these eligibility tests; use the provided records and their documented fields.

State · 1,329 full-atlas cells · all tissues.

Marker genes and cell annotation · Open this population in Cell Browser →

ICE-CREAM (IC) is −log10(P) from a permutation test. An IC score of 3 corresponds to an unadjusted P value of 0.001; 5.5 is the multiple-testing-corrected significance threshold across all metacells. The Significance categories are Significant for IC > 5.5, Nominal for 3 ≤ IC ≤ 5.5, and Nonsignificant for IC < 3. These reports display mean IC scores across full-atlas populations, not the UMAP sample. The categories apply to the displayed scores: a cell-group mean or an average across individual traits is descriptive and is not itself a newly tested P value or a new multiple-testing correction. All scores are retained. Enrichment is not proof of causality or treatment efficacy.

Rows 10,001–11,000 of 12,313; ranked by score descending. Equal values use name/identifier order.

Studies ranked for IPSC.mesodermal_primed
#Trait / studyIndividual trait IDMean IC score
10001CX3CL1/PODXL2 ratioGCST903143262.77e-03
10002CD22/FCRL1 ratioGCST903137572.76e-03
10003FYB1/PPP1R12A ratioGCST903149132.76e-03
10004Plasma pregnenetriol disulfate* levels in chronic kidney diseaseGCST902658642.75e-03
10005Weight-to-muscle ratioGCST902673592.74e-03
10006DOK2 levelsGCST904690292.74e-03
10007CCNE1 levelsGCST904685932.74e-03
10008DCXR levelsGCST904689642.73e-03
10009VEGFC levelsGCST904710362.73e-03
10010MSTN/RGMA ratioGCST903155042.72e-03
10011White blood cell countGCST0046102.72e-03
10012Smoking status (weighted GWA)GCST902673032.71e-03
10013GP2/SELE ratioGCST903149622.71e-03
10014QC T2 FLAIR-to-T1 linear alignment discrepancyGCST900063502.70e-03
10015Hard cheese likingGCST900947782.70e-03
10016IDO1 levelsGCST904695062.70e-03
10017Disorders of the thyroid glandFING000004632.67e-03
10018Varicose veins | circulatory systemUKBB000008932.66e-03
10019CSF1/IL10RB ratioGCST903142842.66e-03
10020DIABLO/PDGFB ratioGCST903144682.65e-03
10021CSF1 levelsGCST904688812.65e-03
10022BCR/DECR1 ratioGCST903134892.65e-03
10023Asthma (only as main-diagnosis) (more control exclusions)FING000001142.64e-03
10024ATG4A/NSFL1C ratioGCST903133682.63e-03
10025Endometrial cancerGCST0064642.62e-03
10026Asthma, unspecified (mode)FING000001202.61e-03
10027MMP3 levelsGCST900120272.59e-03
10028EVI5 levelsGCST904691582.58e-03
10029SHISA5 levelsGCST904706262.58e-03
10030HEG1 levelsGCST904694442.57e-03
10031FUT8/RSPO1 ratioGCST903148912.57e-03
10032IDP SWI T2star right putamenGCST900038682.57e-03
10033GP6/SELP ratioGCST903149702.56e-03
10034OMD/SOST ratioGCST903155852.56e-03
10035COL1A1/OMD ratioGCST903141712.56e-03
10036Plasma X-25279 levels in chronic kidney diseaseGCST902668352.55e-03
10037DEFA1 or DEFA1B levelsGCST904689792.54e-03
10038ThalamNuclei lh volume VLpGCST900027342.54e-03
10039Glycine levelsGCST904973162.53e-03
10040MGLL/MITD1 ratioGCST903154362.53e-03
10041Dihexosylceramide (d18:1/24:0) levelsGCST900253492.53e-03
10042CLPP levelsGCST904687852.52e-03
10043Autoimmune hyperthyroidismFING000001342.51e-03
10044DAG1/PLA2G4A ratioGCST903143802.51e-03
10045Operation year/age first occurred | OperationsUKBB000005702.51e-03
10046MED18/TACC3 ratioGCST903154142.50e-03
10047MPI/TACC3 ratioGCST903154912.50e-03
10048CCL4 levelsGCST900120522.49e-03
10049CRACR2A levelsGCST904688532.49e-03
10050MOG/PTPRN2 ratioGCST903154752.48e-03
10051Prescriptions - thyroid hormone | hormoneUKBB000007052.48e-03
10052Prescriptions - levothyroxine | thyroid hormoneUKBB000006872.48e-03
10053CD300LG/DSG2 ratioGCST903138022.47e-03
10054Sicca syndrome [Sjögren]FING000013042.46e-03
10055F-fruit liking (derived food-liking factor)GCST900947672.45e-03
10056FUCA1 levelsGCST904692752.44e-03
10057Varicose veins of lower extremities | Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classifiedUKBB000008942.42e-03
10058STX8/USP8 ratioGCST903158962.41e-03
10059Depression (broad)GCST0059022.40e-03
10060PCDH17/ROBO1 ratioGCST903156042.39e-03
10061Cholesteryl esters to total lipids ratio in large LDLGCST900928592.39e-03
10062SCLY levelsGCST904705462.39e-03
10063Rheumatoid arthritisGCST0006792.39e-03
10064PSCA levelsGCST904703522.39e-03
10065NOTCH1/TIE1 ratioGCST903155462.38e-03
10066Phosphatidylcholine-O_36:4_[M+H]1+/Phosphatidylcholine-P_36:3_[M+H]1+ levelsGCST900603182.38e-03
10067DOK2/PPP1R12A ratioGCST903145362.37e-03
10068T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 70)GCST903208892.37e-03
10069Platelet distribution width | Blood countUKBB000006482.36e-03
10070BIN2/TMSB10 ratioGCST903135152.36e-03
10071Total Sphingomyelin levelsGCST900258422.36e-03
10072Spermatocele (PheCode 603.2)GCST904761582.35e-03
10073aparc-a2009s lh area G-cingul-Post-ventralGCST900033062.35e-03
10074Illnesses of father - None of the above (group 2) | Family historyUKBB000003462.35e-03
10075FURIN/IGSF3 ratioGCST903148852.34e-03
10076ARHGAP30 levelsGCST904683542.34e-03
10077TGFBI/VASN ratioGCST903159152.34e-03
10078Lung cancer in never smokersGCST902774342.34e-03
10079Urine methylsuccinoylcarnitine levels in chronic kidney diseaseGCST902655092.33e-03
10080EGLN1/FOXO1 ratioGCST903146162.32e-03
10081MTHFSD levelsGCST904699562.31e-03
10082Cholesteryl esters to total lipids in large LDL percentage (UKB data field 23616)GCST902697132.31e-03
10083Broad bean likingGCST900947112.30e-03
10084Osteopenia or other disorder of bone and cartilage (PheCode 743.9)GCST904762612.30e-03
10085RGMB levelsGCST902426472.30e-03
10086AHSP/CA2 ratioGCST903132152.29e-03
10087CholelithiasisGCST904681182.29e-03
10088CELA3A/PLA2G1B ratioGCST903140142.28e-03
10089NAP1L4 levelsGCST904699982.27e-03
10090Microscopic colitisGCST902041442.27e-03
10091FGF21 levelsGCST902747882.27e-03
10092Neoplasm of uncertain behavior of skin (PheCode 173)GCST904755852.26e-03
10093HDLBP levelsGCST900875332.26e-03
10094HeterophoriaFING000006202.25e-03
10095GOLGA3 levelsGCST904693752.25e-03
10096Blood cell traits latent factor 14 (red cell)GCST905592562.24e-03
10097ThalamNuclei lh volume CMGCST900027182.24e-03
10098T1 CAT volume L VIIIaGCST903841272.23e-03
10099Viral and other specified intestinal infectionsFING000014322.23e-03
10100Acute sinusitisFING000000312.23e-03
10101AsthmaGCST0068622.22e-03
10102Tyrosine levelsGCST902434252.22e-03
10103Father's age at death | Family historyUKBB000002412.22e-03
10104CD58 levelsGCST904686382.21e-03
10105NFATC3 levelsGCST904700342.21e-03
10106rfMRI connectivity (ICA100 edge 995)GCST900058482.21e-03
10107MIF/PARK7 ratioGCST903154472.21e-03
10108DNAJC6 levelsGCST904690172.20e-03
10109TNFRSF1A levelsGCST900120152.20e-03
10110GP1BA/SIAE ratioGCST903149592.20e-03
10111GSTA3 levelsGCST904694122.19e-03
10112N-acetylcarnosine levelsGCST901999262.19e-03
10113THTPA levelsGCST904708602.18e-03
10114LY6D levelsGCST904698212.18e-03
10115CDH15 levelsGCST904686682.18e-03
10116CHRDL2 levelsGCST904687512.17e-03
10117Sjögren's syndromeGCST900187002.17e-03
10118Disorders of bilirubin excretion (PheCode 277.4)GCST904757562.17e-03
10119IL15RA levelsGCST904695552.16e-03
10120Diffuse idiopathic skeletal hyperostosis flow scoreGCST901345322.16e-03
10121Urine N1,N12-diacetylspermine levels in chronic kidney diseaseGCST902656832.15e-03
10122Special factor anxiety/tension in mitochondrial haplogroup UGCST902641272.15e-03
10123Benign neoplasm: ColonFING000001712.15e-03
10124Linoleic acid levelsGCST905023112.15e-03
10125Oral glucose tolerance test-2hGCST905664232.14e-03
10126ANGPT1/EGF ratioGCST903132642.14e-03
10127CholelithiasisGCST900185992.14e-03
10128Total concentration of lipoprotein particlesGCST905001032.14e-03
10129Left-hemisphere control network to right-hemisphere dorsal attention network white-matter structural connectivityGCST903027472.14e-03
10130Other infective otitis externaFING000010602.14e-03
10131CEBPB/NADK ratioGCST903140062.12e-03
10132SEMA4C levelsGCST904705722.11e-03
10133CataractsGCST900185942.11e-03
10134rfMRI amplitudes (ICA100 node 40)GCST900046282.11e-03
10135aparc-a2009s rh thickness G+S-cingul-AntGCST900036822.11e-03
10136Retention of urine (PheCode 599.2)GCST904761502.10e-03
10137Biological Sibling: Cancer, SkinGCST904763692.10e-03
10138APP levelsGCST904683442.09e-03
10139Cervicobrachial syndromeFING000002662.09e-03
10140FCRL5/ICAM3 ratioGCST903148022.08e-03
10141NID1 levelsGCST904700472.08e-03
10142Other and unspecified rosaceaFING000009512.07e-03
10143Ulcerative colitisGCST904681522.06e-03
10144F-dessert liking (derived food-liking factor)GCST900947542.06e-03
10145Physical activity (Total log acceleration)GCST900614082.06e-03
10146BIN1 levelsGCST900907572.05e-03
10147Hippocampal subfield left CA3 volume (body)GCST902679402.04e-03
10148Allergy/adverse effect of penicillin | injuries & poisoningsUKBB000000282.04e-03
10149Asthma (more control exclusions)FING000001132.04e-03
10150PF4 levelsGCST904702112.03e-03
10151Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T237ECGU0002372.03e-03
10152PLA2G4A/SNX9 ratioGCST903156702.03e-03
10153MMP10 levelsGCST904699152.03e-03
10154CDC27 levelsGCST904686642.03e-03
10155KLK15 levelsGCST904697012.02e-03
10156KIFBP/TACC3 ratioGCST903152492.02e-03
10157Pregnanediol-3-glucuronide levelsGCST901999172.01e-03
10158CD40/TNFRSF14 ratioGCST903138302.00e-03
10159NECTIN2/NPDC1 ratioGCST903155282.00e-03
10160PPP1R9B levelsGCST904703051.99e-03
10161Alkenylphosphatidylcholine (P-16:0/16:0) levelsGCST900255631.99e-03
10162Abdominal subcutaneous adipose tissue volumeGCST900166721.98e-03
10163Cauliflower likingGCST900947271.97e-03
10164SPRY2/YTHDF3 ratioGCST903158811.97e-03
10165Pulse wave Arterial Stiffness index | Arterial stiffnessUKBB000007241.97e-03
10166DNAJB1/METAP2 ratioGCST903145091.97e-03
10167CD244/FCRL6 ratioGCST903137651.96e-03
10168MTSS1 levelsGCST904699601.96e-03
10169IL6 expression at 6 weeks in whole blood upon Bbmix moi30 stimulation in Lyme borreliosisGCST902757891.95e-03
10170Retinal venular widthGCST902704001.95e-03
10171Mean platelet volumeGCST0045991.94e-03
10172MET/PTPRF ratioGCST903154351.94e-03
10173NFATC1 levelsGCST904700331.94e-03
10174APP/BIN2 ratioGCST903133161.93e-03
10175Myasthenia gravisGCST900930611.93e-03
10176MGLL/STK4 ratioGCST903154431.93e-03
10177DLK1 levelsGCST904690031.92e-03
10178Cerebrospinal fluid methylmalonate (MMA) levelsGCST903182431.92e-03
10179Red blood cell countGCST0046011.91e-03
10180MCFD2 levelsGCST904698731.91e-03
10181Chronic lower respiratory diseasesFING000002901.91e-03
10182HCLS1/LAT ratioGCST903150411.91e-03
10183Gamma glutamyl transpeptidaseGCST900187341.91e-03
10184CELA3A/KIRREL2 ratioGCST903140131.90e-03
10185Urate levelsGCST0017911.90e-03
10186CD79B levelsGCST904686481.90e-03
10187CLEC4M levelsGCST904687751.90e-03
10188mean corpuscular hemoglobin concentration (MCHC, maximum, inv-norm transformed)GCST904754521.90e-03
10189Docosahexaenoic acid levelsGCST905022581.90e-03
10190Autorefraction - 6mm strong meridian angle (left) | EyesightUKBB000000771.89e-03
10191HDAC8 levelsGCST904694381.89e-03
10192TNFRSF1B levelsGCST900120261.89e-03
10193ENG/TNFRSF10C ratioGCST903146501.89e-03
10194SORT1/ST6GAL1 ratioGCST903158691.88e-03
10195Abdominal subcutaneous adipose tissueGCST902673471.88e-03
10196Visceral adipose tissueGCST902673571.88e-03
10197Right-hemisphere control network to right-hemisphere control network white-matter structural connectivityGCST903028341.87e-03
10198COX5B/FXN ratioGCST903141991.87e-03
10199SYAP1 levelsGCST904707921.87e-03
10200CD40LG/TNFSF14 ratioGCST903138271.86e-03
10201FCRL2/KLB ratioGCST903147981.86e-03
10202Degeneration of macula and posterior pole of retina (PheCode 362.2)GCST904758491.85e-03
10203MESD/WWP2 ratioGCST903154261.85e-03
10204BCR/ITGB1BP2 ratioGCST903134941.85e-03
10205NUDT5/TXNRD1 ratioGCST903155821.84e-03
10206CLMP/PIK3IP1 ratioGCST903141341.84e-03
10207FXN/METAP1D ratioGCST903148971.83e-03
10208CRACR2A/DNMBP ratioGCST903142261.83e-03
10209Hernia abdominopelvic cavityGCST900860871.82e-03
10210CD69/CEP43 ratioGCST903138671.82e-03
10211CERT/PRTFDC1 ratioGCST903140291.81e-03
10212KIR2DL3 levelsGCST904696851.81e-03
10213CRISP3 levelsGCST904688661.80e-03
10214FCER2/FCRL1 ratioGCST903147891.80e-03
10215ALDH1A1/RBKS ratioGCST903132471.79e-03
10216Alkylphosphatidylcholine (O-32:1) levelsGCST900249231.79e-03
10217PPP1R12A/VEGFC ratioGCST903157151.79e-03
10218wg rh intensity-contrast transversetemporalGCST900038601.79e-03
10219HPCAL1/LAT ratioGCST903150721.78e-03
10220ERBIN/SNAP29 ratioGCST903146971.78e-03
10221SPARC/TACC3 ratioGCST903158721.77e-03
10222TACC3/TBC1D23 ratioGCST903159001.77e-03
10223Other specified disorders of external earFING000011041.75e-03
10224NPC2 levelsGCST904700681.75e-03
10225CCN1 levelsGCST904685871.75e-03
10226Intestinal infectious diseasesFING000006891.75e-03
10227RAB11FIP3 levelsGCST904704041.74e-03
10228CRLF1 levelsGCST904688681.74e-03
10229CWC15 levelsGCST904689201.74e-03
10230Unspecified acute lower respiratory infectionFING000013981.74e-03
10231DARS1 levelsGCST904689471.73e-03
10232CLEC4G/NELL2 ratioGCST903141221.73e-03
10233Other disorders of veinsFING000010401.72e-03
10234CRIM1 levelsGCST904688631.72e-03
10235Phospholipids in very large HDLGCST905004511.72e-03
10236NECTIN4 levelsGCST904700211.72e-03
10237Hair colour (natural, before greying): Light brown (UKB data field 1747_3)GCST900418381.72e-03
10238CXCL5/SPARC ratioGCST903143551.72e-03
10239NBL1/TGFBR2 ratioGCST903155151.71e-03
10240C1QA levelsGCST904684851.71e-03
10241Melanomas of skin, dx or hx (PheCode 172.1)GCST904755771.71e-03
10242IDP dMRI TBSS MO Medial lemniscus LGCST900039611.71e-03
10243Disorders of lacrimal systemFING000004411.71e-03
10244PPP1R2/TACC3 ratioGCST903157191.70e-03
10245NPDC1/TAFA5 ratioGCST903155501.70e-03
10246Sphingomyelin (d18:1/14:0) levels/Sphingomyelin (d16:1/16:0) levelsGCST900251151.69e-03
10247NTN1 levelsGCST902420471.69e-03
10248White blood cell countGCST900023751.69e-03
10249Pulse wave peak to peak time | Arterial stiffnessUKBB000007251.68e-03
10250CA5A levelsGCST904685141.68e-03
10251WFDC5 levelsGCST900895981.68e-03
10252CD244/EDAR ratioGCST903137641.68e-03
10253Other non-epithelial cancer of skin | neoplasmsUKBB000006151.68e-03
10254GNPDA2 levelsGCST904693741.66e-03
10255CX3CL1/EPHB6 ratioGCST903143241.66e-03
10256Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T485ECGA0004851.65e-03
10257Varicose veins of lower extremity | circulatory systemUKBB000008951.65e-03
10258Use of antiglaucoma preparations and mioticsFING000014091.64e-03
10259Status post-amiFING000013331.64e-03
10260Ectopic pregnancyGCST902728831.64e-03
10261ICD10 O00: Ectopic pregnancyGCST904542271.64e-03
10262FCGR2A/FCGR2B ratioGCST903147931.63e-03
10263SSC4D/TNFSF10 ratioGCST903158871.63e-03
10264FYB1/PDGFB ratioGCST903149121.63e-03
10265SH3BP1 levelsGCST904706191.62e-03
10266Blood cell traits latent factor 12 (red cell)GCST905592541.62e-03
10267DFFA/FOXO1 ratioGCST903144561.62e-03
10268Lysophosphatidylcholine (24:0) [sn2] levelsGCST900254261.62e-03
10269TMSB10/ZBTB16 ratioGCST903159261.61e-03
10270Type 2 diabetesGCST900860711.60e-03
10271Non-cancer illness code, self-reported - glaucoma | Medical conditionsUKBB000005111.60e-03
10272IGBP1 levelsGCST904695211.60e-03
10273KDR levelsGCST904696721.60e-03
10274Loud music exposure frequency | HearingUKBB000004101.59e-03
10275Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T484ECGA0004841.59e-03
10276ICD10 O26.6: Liver disorders in pregnancy, childbirth and puerperiumGCST904542371.59e-03
10277MANSC1/PODXL ratioGCST903153721.58e-03
10278TIMP4 levelsGCST904708721.58e-03
10279PSAP levelsGCST904703511.58e-03
10280SNRPB2 levelsGCST904706971.58e-03
10281SULT2A1 levelsGCST904707821.57e-03
10282TAX1BP1 levelsGCST904708081.57e-03
10283GZMA levelsGCST902413231.57e-03
10284HCLS1/TMSB10 ratioGCST903150431.57e-03
10285BLVRB/HAGH ratioGCST903135241.55e-03
10286CD40/CRELD2 ratioGCST903138111.55e-03
10287Right-hemisphere visual network to right-hemisphere dorsal attention network white-matter structural connectivityGCST903027761.55e-03
10288Acute bronchitisFING000000211.55e-03
10289CA12 levelsGCST904685071.55e-03
10290Flavonifractor sp002159265 abundance in stoolGCST900324001.54e-03
10291Cancer of urinary organs (incl. kidney and bladder) (PheCode 189)GCST904755931.54e-03
10292SNX15 levelsGCST904706991.54e-03
10293CDSN/LY6D ratioGCST903139971.54e-03
10294Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T483ECGA0004831.53e-03
10295PGF levelsGCST900119991.52e-03
10296Acute appendicitisFING000000171.51e-03
10297Breast cancerGCST900185791.51e-03
10298Alkylphosphatidylcholine (O-16:0/16:0) levelsGCST900249131.51e-03
10299OTUD6B levelsGCST904701361.50e-03
10300FKBP5/MITD1 ratioGCST903148441.50e-03
10301CEACAM8/MMP9 ratioGCST903140021.50e-03
10302T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 24)GCST903205871.50e-03
10303GPR15L levelsGCST904693961.50e-03
10304AXIN1/SRPK2 ratioGCST903134171.49e-03
10305Nontoxic uninodular goiter (PheCode 241.1)GCST904756401.49e-03
10306ANG/RARRES2 ratioGCST903132711.49e-03
10307FOXJ3 levelsGCST904692641.48e-03
10308Lysophosphatidylcholine (22:0) [sn2] levelsGCST900241761.48e-03
10309NAGK levelsGCST904699951.48e-03
10310BMP10 levelsGCST904684521.47e-03
10311EBI3_IL27/VCAM1 ratioGCST903145721.47e-03
10312CDKN2D/FOXO1 ratioGCST903139851.46e-03
10313Wheeze or whistling in the chest in last year (UKB data field 2316)GCST900436141.46e-03
10314GUCA2A/LGALS4 ratioGCST903149981.46e-03
10315KLK11/KLK8 ratioGCST903152541.45e-03
10316FCAR/LY96 ratioGCST903147881.45e-03
10317Physical activityGCST900933221.45e-03
10318Sleep apnea with BMI < 30GCST906247971.45e-03
10319BAG6/BMP6 ratioGCST903134501.45e-03
10320LAT/VASH1 ratioGCST903152891.44e-03
10321ESAM/VSIR ratioGCST903147211.44e-03
10322ENO2/MGLL ratioGCST903146631.44e-03
10323Brussel sprout likingGCST900947141.44e-03
10324ABL1/PDLIM7 ratioGCST903131501.43e-03
10325BOLA2 or BOLA2B levelsGCST904684601.42e-03
10326BACH1/CD2AP ratioGCST903134351.42e-03
10327DTI TBSS MO Medial lemniscus RGCST903846281.42e-03
10328CA4/SELE ratioGCST903135871.41e-03
10329METAP2/RILP ratioGCST903154331.41e-03
10330ENG/NCAM2 ratioGCST903146471.41e-03
10331DECR1/FXN ratioGCST903144461.41e-03
10332T1 CAT volume R RightThalamusGCST903840971.41e-03
10333JAM2/RGMB ratioGCST903152371.41e-03
10334creatinine (minimum, inv-norm transformed)GCST904752321.41e-03
10335FADD/NFATC1 ratioGCST903147711.41e-03
10336FCER2/TCL1A ratioGCST903147901.40e-03
10337FUT8/SPARC ratioGCST903148931.40e-03
10338IL10RB levelsGCST904695451.39e-03
10339MICB or MICA levelsGCST904699051.39e-03
10340Attendance/disability/mobility allowance - Disability living allowance | Other sociodemographic factorsUKBB000000581.38e-03
10341PPME1 levelsGCST904702981.38e-03
10342PLIN1/SNCG ratioGCST903156771.38e-03
10343Right-hemisphere visual network to right-hemisphere default mode network white-matter structural connectivityGCST903027801.38e-03
10344LYPD8 levelsGCST904698291.37e-03
10345Calcium levelsGCST900259901.37e-03
10346CXCL9 levelsGCST904689351.37e-03
10347Right-hemisphere dorsal attention network to pallidum white-matter structural connectivityGCST903028091.37e-03
10348CDC42BPB levelsGCST904686661.37e-03
10349RARRES2/ST6GAL1 ratioGCST903157591.36e-03
10350Serum phosphate levelsGCST900259481.36e-03
10351Autoimmune diseases excluding thyroid diseasesFING000001321.36e-03
10352Biological Father: Cancer, SkinGCST904752401.35e-03
10353Blood cell traits latent factor 3 (white cell)GCST905592451.35e-03
10354Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T491ECGA0004911.35e-03
10355LAMA4/PDGFB ratioGCST903152731.35e-03
10356CCL13 levelsGCST904685651.35e-03
10357CHI3L1/PRSS8 ratioGCST903140441.34e-03
10358CD22/FCER2 ratioGCST903137561.34e-03
10359F7/PROC ratioGCST903147441.34e-03
10360Preterm labour and deliveryFING000012091.34e-03
10361Platelet distribution widthGCST900024011.34e-03
10362AHSG levelsGCST904682631.34e-03
10363Myasthenia gravisGCST904321561.33e-03
10364OsteoporosisFING000009141.33e-03
10365ASGR2 levelsGCST904683761.33e-03
10366HTRA2/SIAE ratioGCST903150971.32e-03
10367MIF/SUSD2 ratioGCST903154521.32e-03
10368TNFRSF13B/TNFRSF9 ratioGCST903159321.32e-03
10369BIN2/FYB1 ratioGCST903135051.31e-03
10370CDNF levelsGCST904686861.31e-03
10371NHLRC3 levelsGCST904700461.31e-03
10372IGFBP3 levelsGCST901026241.31e-03
10373TAFA5 levelsGCST904708001.30e-03
10374DKK1/ZBTB16 ratioGCST903144861.30e-03
10375CCN2/SPINT2 ratioGCST903137161.29e-03
10376DNAJA2/HCLS1 ratioGCST903145021.29e-03
10377MANF/PRDX5 ratioGCST903153651.29e-03
10378SOD3 levelsGCST904707061.29e-03
10379IDP dMRI TBSS ISOVF Corticospinal tract RGCST900044831.29e-03
10380Hypothyroidism (PheCode 244)GCST904756471.28e-03
10381DCTN1/FXN ratioGCST903144301.28e-03
10382Alanine aminotransferase levelsGCST902786171.28e-03
10383Citrulline levelsGCST902434581.28e-03
10384GP6/LGALS8 ratioGCST903149641.27e-03
10385X-21736 levelsGCST902005841.27e-03
10386PSAP levelsGCST904265861.27e-03
10387CLIP2/DAB2 ratioGCST903141241.27e-03
10388Lignoceroylcarnitine (C24) levelsGCST902001371.26e-03
10389Facial pigmentation measurement (polar light)GCST900022841.26e-03
10390DNAJB2 levelsGCST904690131.26e-03
10391KRT18 levelsGCST904697161.26e-03
10392LY6D/NECTIN4 ratioGCST903153441.26e-03
10393GKN2 levelsGCST900894131.26e-03
10394Blood urea nitrogen levelsGCST900187281.26e-03
10395PRTFDC1 levelsGCST904703461.26e-03
10396SMAD2 levelsGCST904706761.25e-03
10397APP/PPP1R12A ratioGCST903133301.25e-03
10398TNFRSF4 levelsGCST904709131.25e-03
10399HippSubfield rh volume presubiculum-bodyGCST900026971.25e-03
10400CXCL16/NOTCH1 ratioGCST903143391.25e-03
10401CRIP2/SNCG ratioGCST903142621.24e-03
10402aparc-a2009s lh area S-precentral-sup-partGCST900033651.24e-03
10403Omega-3 fatty acids to Omega-6 fatty acids ratioGCST905020771.24e-03
10404Cardiometabolic multimorbidityGCST902747231.24e-03
10405NOTCH3/PTPRS ratioGCST903155471.24e-03
10406Omega-3 fatty acid levelsGCST905020641.24e-03
10407SPINT1 levelsGCST902417171.24e-03
10408Actinic keratosis (PheCode 702.1)GCST904762041.23e-03
10409Gouty arthropathy (PheCode 274.11)GCST904757381.22e-03
10410ECE1 levelsGCST904690611.22e-03
10411MANF/SNX9 ratioGCST903153681.22e-03
10412PLA2G2A levelsGCST904702471.21e-03
10413T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 88)GCST903209071.20e-03
10414Disorders of musclesFING000004441.20e-03
10415CASP8/PPP3R1 ratioGCST903136541.20e-03
10416SCT levelsGCST904705571.20e-03
10417SEPTIN8 levelsGCST904705781.20e-03
10418NCR3 levelsGCST900881791.20e-03
10419NOMO1 levelsGCST904700601.20e-03
10420Seropositive rheumatoid arthritis, strict definitionFING000012971.19e-03
10421GIT1 levelsGCST904693511.19e-03
10422Wheeze or whistling in the chest in last year | BreathingUKBB000009121.19e-03
10423CDH5/NOTCH1 ratioGCST903139571.19e-03
10424MPIG6B/SUSD1 ratioGCST903154871.19e-03
10425IL6ST/LIFR ratioGCST903151661.19e-03
10426FXYD5 levelsGCST904692831.19e-03
10427Phosphatidylcholine_38:5_[M+H]1+/Phosphatidylethanolamine_41:5_[M+H]1+/Phosphatidate_43:6_[M+NH4]1+ levelsGCST900603951.19e-03
10428CDH17/SPINT1 ratioGCST903139441.19e-03
10429TPMT levelsGCST904709451.18e-03
10430WNT9A levelsGCST904710791.17e-03
10431DTI autoptx L3 unc r tractGCST903852191.17e-03
10432Extrapyramidal disease and abnormal movement disorders (PheCode 333)GCST904758311.17e-03
10433Malignant neoplasm of bronchus and lung, excluding all cancers (controls excluding all cancers)FING000007561.17e-03
10434CELA3A levelsGCST904687021.17e-03
10435TNFSF12 levelsGCST904709191.17e-03
10436GAS6 levelsGCST904693051.17e-03
10437LGALS7 or LGALS7B levelsGCST904697631.16e-03
10438Substance use, excluding alcoholFING000013421.16e-03
10439MMP8/OLR1 ratioGCST903154641.16e-03
10440TNFSF8 levelsGCST904709231.16e-03
10441Disorders of plasma protein metabolism (PheCode 270.3)GCST904757091.16e-03
10442ALCAM/IL1RL2 ratioGCST903132381.15e-03
10443HLA-E levelsGCST904694591.15e-03
10444Mononeuropathies of upper limb | Nerve, nerve root and plexus disordersUKBB000004811.15e-03
10445Soy sauce likingGCST900948441.15e-03
10446BST2 levelsGCST904684751.14e-03
10447F11R/PARK7 ratioGCST903147231.14e-03
10448AXL/MSR1 ratioGCST903134221.14e-03
10449AIF1 levelsGCST904682671.14e-03
10450SarcoidosisGCST900186981.14e-03
10451DTI autoptx L1 ifo r tractGCST903851521.13e-03
10452MAPKAPK2 levelsGCST904698581.12e-03
10453KIRREL2/PLA2G1B ratioGCST903152511.12e-03
10454Macular degeneration, wet (PheCode 362.22)GCST904758521.11e-03
10455BCR/PLXNA4 ratioGCST903134971.11e-03
10456T1 FreeSurfer aseg Left-PutamenGCST903841451.11e-03
10457PsoriasisGCST900190161.10e-03
10458IDS levelsGCST904695071.10e-03
10459Beans likingGCST900946991.09e-03
10460NINJ1 levelsGCST904700491.09e-03
10461FTCD levelsGCST904692741.08e-03
10462Smoking and associated risk behaviours (confirmatory factor analysis Factor 6)GCST903093411.08e-03
10463CAPG levelsGCST904685371.07e-03
10464Malignant neoplasm of thyroid gland, excluding all cancers (controls excluding all cancers)FING000007771.07e-03
10465Operation code - inguinal hernia repair | OperationsUKBB000005601.07e-03
10466LECT2 levelsGCST904697511.07e-03
10467lymphocyte (absolute count, maximum, inv-norm transformed)GCST904754231.07e-03
10468DermatitisFING000004011.07e-03
10469NOS3 levelsGCST904700641.06e-03
10470Phosphatidylcholine levelsGCST904992481.06e-03
10471BACH1/NFATC1 ratioGCST903134441.06e-03
10472LTBR levelsGCST902431761.06e-03
10473Takes medication for gout?GCST904763821.06e-03
10474NFATC1/SPRY2 ratioGCST903155391.06e-03
10475lymphocyte (fraction, minimum, inv-norm transformed)GCST904754381.06e-03
10476LRPAP1 levelsGCST904698001.06e-03
10477RAB27B levelsGCST904704051.05e-03
10478TGFBR2/TNFRSF1A ratioGCST903159181.05e-03
10479Endometriosis diagnosis and infertility diagnosis occurring togetherFING000004991.04e-03
10480PDGFB levelsGCST904701891.04e-03
10481CIAPIN1/PLA2G4A ratioGCST903140651.04e-03
10482FKBP5/TBCC ratioGCST903148491.04e-03
10483Myocardial infarction (PheCode 411.2)GCST900439541.04e-03
10484IGSF8/VSIR ratioGCST903151411.04e-03
10485LYZL2 levelsGCST904698331.04e-03
10486CNDP1/F9 ratioGCST903141471.04e-03
10487Posterior thigh muscle fat infiltration percentageGCST902673551.03e-03
10488Skin cancerGCST904755751.03e-03
10489CLPS/PLA2G1B ratioGCST903141401.03e-03
10490X-12095--N1-methyl-3-pyridone-4-carboxamide levelsGCST902437011.03e-03
10491CXCL5/SERPINE1 ratioGCST903143541.03e-03
10492PLPBP levelsGCST904702601.02e-03
10493NT5C3A/PRDX5 ratioGCST903155671.02e-03
10494Principal component-derived dietary pattern 40GCST901330451.02e-03
10495AKT1S1 levelsGCST904682761.02e-03
10496AMBN levelsGCST904682871.02e-03
10497RELT levelsGCST904704531.02e-03
10498CCN2/DKK1 ratioGCST903137101.02e-03
10499CCL5/LAMA4 ratioGCST903137031.01e-03
10500Triglyceride levels in chylomicrons and extremely large VLDLGCST905010681.01e-03
10501LPP levelsGCST904697901.01e-03
10502Varicose veinsFING000014161.01e-03
10503PDLIM7 levelsGCST904701981.00e-03
10504FADD/GRAP2 ratioGCST903147661.00e-03
10505MANF/PDGFB ratioGCST903153609.98e-04
10506Omega-3 fatty acids to total fatty acids percentageGCST905024639.96e-04
10507ANG levelsGCST904683079.95e-04
10508Phosphate levels (UKB data field 30810)GCST904680949.92e-04
10509RIDA levelsGCST904704699.92e-04
10510COL18A1/RETN ratioGCST903141709.86e-04
10511Papulosquamous disordersFING000011449.84e-04
10512CPXM2 levelsGCST904688509.81e-04
10513Operative procedures - Primary total prosthetic replacement of knee joint using cement | Summary OperationsUKBB000005889.79e-04
10514Concentration of HDL particlesGCST904974069.77e-04
10515Citrate levelsGCST904972009.77e-04
10516Hashimoto thyroiditisGCST900186359.77e-04
10517Triglyceride to phosphoglyceride ratioGCST904544839.69e-04
10518CD7 levelsGCST904686499.59e-04
10519GCNT1 levelsGCST904693199.58e-04
10520SORCS2 levelsGCST904707089.52e-04
10521CCL5/CXCL3 ratioGCST903137009.46e-04
10522FEN1 levelsGCST904692139.46e-04
10523SMNDC1 levelsGCST904706819.43e-04
10524IMMT levelsGCST904696099.43e-04
10525MSRA/PRDX5 ratioGCST903154979.40e-04
10526Phospholipids in medium HDLGCST904986419.39e-04
10527TNFRSF8 levelsGCST904709159.38e-04
10528Reimbursement for rheumatic diseasesFING000012479.36e-04
10529HyperthyroidismGCST903193199.31e-04
10530UBXN1 levelsGCST904710049.31e-04
10531Total lipids in small HDL (UKB data field 23573)GCST902696709.31e-04
10532APP/TMSB10 ratioGCST903133329.23e-04
10533KLRB1/KLRD1 ratioGCST903152609.22e-04
10534CD63/EDAR ratioGCST903138649.19e-04
10535DTI autoptx MD fmi tractGCST903852319.16e-04
10536ARHGAP1/SPARC ratioGCST903133449.14e-04
10537B4GALT1/IFNGR1 ratioGCST903134309.14e-04
10538PneumoniaGCST900186819.05e-04
10539LBP levelsGCST904697439.05e-04
10540SERPINB1/SERPINB6 ratioGCST903158268.99e-04
10541Eosinophill percentage | Blood countUKBB000002078.98e-04
10542CAMSAP1 levelsGCST904685358.95e-04
10543APBB1IP/NADK ratioGCST903132988.95e-04
10544Eosinophill percentage (UKB data field 30210)GCST904680698.94e-04
10545Athlete's foot (PheCode 110.12)GCST904755638.92e-04
10546CA13/TYMP ratioGCST903135688.91e-04
10547LAYN/VWC2 ratioGCST903152938.91e-04
10548Histidine levelsGCST904974798.90e-04
10549aparc-a2009s lh thickness S-postcentralGCST900036698.90e-04
10550EEF1D levelsGCST904690758.87e-04
10551CLEC1B/ITGB5 ratioGCST903140948.86e-04
10552IDP dMRI TBSS ISOVF Genu of corpus callosumGCST900044798.85e-04
10553Breast cancer [female] | neoplasmsUKBB000001088.80e-04
10554AK1/NSFL1C ratioGCST903132248.78e-04
10555Disorders of iris and ciliary body (PheCode 379.5)GCST904758998.73e-04
10556FCRL1/TREML2 ratioGCST903147978.70e-04
10557MMP9/PLAUR ratioGCST903154708.70e-04
10558PTN levelsGCST904703748.67e-04
10559Eosinophil percentage of white cellsGCST900023828.66e-04
10560DOK2/LACTB2 ratioGCST903145328.63e-04
10561GPKOW/PXN ratioGCST903149788.60e-04
10562NTN4 levelsGCST902420498.59e-04
10563KLF4 levelsGCST904696948.57e-04
10564N-acetylphenylalanine levelsGCST902006778.55e-04
10565Anal and rectal conditions | digestiveUKBB000000298.53e-04
10566PLXNB2 levelsGCST904702668.52e-04
10567T1 FreeSurfer BA rh BA4p exvivo areaGCST903855528.49e-04
10568T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 128)GCST903206918.49e-04
10569SNAP23/ZBTB16 ratioGCST903158588.43e-04
10570CNTNAP2/DPP6 ratioGCST903141688.43e-04
10571PGF levelsGCST904702188.42e-04
10572FAM3B/FUT3_FUT5 ratioGCST903147778.40e-04
10573BCR/GOPC ratioGCST903134918.39e-04
10574NCF2 levelsGCST904700068.35e-04
10575Plasma lysine levels in chronic kidney diseaseGCST902654598.31e-04
10576FKBP1B/TGFB1 ratioGCST903148368.27e-04
10577Psoriasis vulgarisFING000012248.25e-04
10578Degenerative skin conditions and other dermatoses (PheCode 702)GCST904762028.25e-04
10579DKK1/PDGFA ratioGCST903144758.25e-04
10580IL12B levelsGCST902747988.23e-04
10581Operation code - tonsillectomy +/- adenoids | OperationsUKBB000005678.16e-04
10582Myocardial fractal dimension (slice 7)GCST900002938.15e-04
10583Thyrotoxicosis with diffuse goitreFING000013618.14e-04
10584Suggestive for eosinophilic asthmaFING000013448.12e-04
10585Hair colour (natural, before greying) - Dark brown | Sun exposureUKBB000002978.11e-04
10586APP/CD40LG ratioGCST903133198.06e-04
10587T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 118)GCST903206818.06e-04
10588Modified Stumvoll Insulin Sensitivity Index (adjusted for BMI)GCST902675737.99e-04
10589Takes medication for circulatory problem?GCST904752187.98e-04
10590Alkylphosphatidylcholine (O-34:1) levelsGCST900255517.97e-04
10591GP2/LGALS4 ratioGCST903149607.96e-04
10592Ovarian cancer-related tumor marker CA 125 levelsGCST900120787.95e-04
10593SPINT1 levelsGCST904707277.95e-04
10594TGFBI levelsGCST904708457.93e-04
10595CD46/SELP ratioGCST903138347.92e-04
10596PPP1R12A/SKAP2 ratioGCST903157107.92e-04
10597EIF4B/IPCEF1 ratioGCST903146227.91e-04
10598Cholesteryl esters in small HDL (UKB data field 23576)GCST902696737.89e-04
10599Benign neoplasm of eye, uveal (PheCode 224.1)GCST904756297.87e-04
10600SORT1/VSIR ratioGCST903158707.85e-04
10601Right-hemisphere visual network to hippocampus white-matter structural connectivityGCST903027857.85e-04
10602Microalbumin in urine | Urine assaysUKBB000004677.85e-04
10603SDCCAG8 levelsGCST904705607.80e-04
10604PLAT levelsGCST904702507.78e-04
10605Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T11ECGA0000117.75e-04
10606Omega-3 fatty acids to Omega-6 fatty acids ratioGCST905023997.73e-04
10607Other non-epithelial cancer of skin (PheCode 172.2)GCST904755807.67e-04
10608MGAT2 levelsGCST900895607.66e-04
10609Seborrheic keratosis (PheCode 702.2)GCST904762067.66e-04
10610CCL15/CCL23 ratioGCST903136817.63e-04
10611Left-hemisphere dorsal attention network to putamen white-matter structural connectivityGCST903027037.60e-04
10612Malignant neoplasm of rectum, excluding all cancers (controls excluding all cancers)FING000007717.58e-04
10613RABGAP1L levelsGCST904704167.57e-04
10614Blood cell traits latent factor 10 (platelet)GCST905592527.57e-04
10615Hair colour (natural, before greying) - Light brown | Sun exposureUKBB000002987.56e-04
10616Docosahexaenoic acid to total fatty acids percentageGCST905019997.50e-04
10617RELL1 levelsGCST902426257.49e-04
10618IDP dMRI TBSS MD Pontine crossing tractGCST900040287.48e-04
10619IDP dMRI TBSS L3 Posterior limb of internal capsule RGCST900041897.44e-04
10620NECTIN4/TGFBR2 ratioGCST903155357.37e-04
10621VPS53 levelsGCST904710487.36e-04
10622Right molecular layer hippocampal volume (body)GCST902679757.36e-04
10623F2R/TMSB10 ratioGCST903147387.34e-04
10624EPO levelsGCST904691367.34e-04
10625CSTB levelsGCST900120067.33e-04
10626Plasma 11beta-hydroxyandrosterone glucuronide levels in chronic kidney diseaseGCST902643217.32e-04
10627HippSubfield lh volume subiculum-bodyGCST900026697.26e-04
10628Breathing problems responsible for leaving job | Employment historyUKBB000001127.23e-04
10629PLIN1 levelsGCST904702587.22e-04
10630LAT/SPARC ratioGCST903152887.22e-04
10631Curry likingGCST900947507.21e-04
10632SNAP29/SNX9 ratioGCST903158597.20e-04
10633AHNAK2 levelsGCST904682607.20e-04
10634SLAMF1 levelsGCST904706497.18e-04
10635NECTIN4/SPINK5 ratioGCST903155347.16e-04
10636ARHGEF1 levelsGCST904683597.16e-04
10637Nervonoylcarnitine (C24:1) levelsGCST902001437.14e-04
10638CDH5/PCDH17 ratioGCST903139587.12e-04
10639ATP5IF1/F2R ratioGCST903133847.06e-04
10640USO1 levelsGCST904710187.06e-04
10641Triacylglycerol_50:3_[M+NH4]1+ levelsGCST900604687.06e-04
10642Nasal polypFING000008587.03e-04
10643NT5C levelsGCST904700927.03e-04
10644CEP43/PLXNB3 ratioGCST903140206.96e-04
10645SMAD1 levelsGCST904706756.93e-04
10646Takes medication for Glaucoma?GCST904753846.92e-04
10647Ulcerative enterocolitisFING000013916.92e-04
10648SERPINA3 levelsGCST904705836.91e-04
10649CASP3/SERPINE1 ratioGCST903136436.90e-04
10650CD28 levelsGCST904686166.85e-04
10651GRAP2/LACTB2 ratioGCST903149806.83e-04
10652CDC37/SNX9 ratioGCST903139366.83e-04
10653Asthma/COPD (KELA code 203)FING000001216.83e-04
10654Calculus of ureter (PheCode 594.3)GCST904761476.79e-04
10655CRELD2/ERP44 ratioGCST903142536.79e-04
10656CLEC4G levelsGCST904687746.78e-04
10657T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 111)GCST903209306.77e-04
10658CTRC/KIRREL2 ratioGCST903143096.72e-04
10659PEAR1/TREML2 ratioGCST903156456.67e-04
10660MED18 levelsGCST904698806.66e-04
10661FABP1/SULT2A1 ratioGCST903147556.65e-04
10662CNTN1 levelsGCST904688036.61e-04
10663B2M levelsGCST904684096.60e-04
10664PAFAH1B3 levelsGCST904701456.60e-04
10665CD74 levelsGCST904686476.59e-04
10666ATF6 levelsGCST902408166.58e-04
10667PI3 levelsGCST904702306.58e-04
10668AsthmaGCST900860476.57e-04
10669APP/LAMA4 ratioGCST903133256.57e-04
10670TBC1D5 levelsGCST904708116.56e-04
10671Pregnenetriol disulfate levelsGCST902002386.55e-04
10672AcneFING000000106.54e-04
10673CELA3A/CTRB1 ratioGCST903140116.53e-04
10674DKK1/VTA1 ratioGCST903144856.52e-04
10675Other serious medical condition/disability diagnosed by doctor | Medical conditionsUKBB000006196.51e-04
10676IL15/NCR1 ratioGCST903151506.51e-04
10677DXO levelsGCST904690556.49e-04
10678Neutrophil percentage of granulocytesGCST0046236.47e-04
10679Skin cancerGCST904751896.47e-04
10680Chronic sinusitisFING000002986.44e-04
10681HSPA1A/MGLL ratioGCST903150836.42e-04
10682GM3 ganglioside (d18:1/24:0) levelsGCST900253406.42e-04
10683FCGR2B/NOS3 ratioGCST903147946.41e-04
10684CXCL9 levelsGCST902747846.40e-04
10685CHMP6 levelsGCST904687476.39e-04
10686CCL8 levelsGCST904223466.38e-04
10687C4BPB/ENTPD5 ratioGCST903135566.35e-04
10688CNDP1/EGFR ratioGCST903141466.34e-04
10689HVEM on Terminally Differentiated CD4+ T cellGCST900018796.34e-04
10690PIK3AP1 levelsGCST904702336.32e-04
10691Medication use (diuretics)GCST900187656.29e-04
10692CCL17/PDGFB ratioGCST903136886.27e-04
10693MANF/SDC4 ratioGCST903153676.26e-04
10694KIR3DL1 levelsGCST904696876.24e-04
10695GZMB levelsGCST904694246.23e-04
10696Concentration of small HDL particlesGCST900929516.23e-04
10697Cysteine-glutathione disulfide levelsGCST901997846.20e-04
10698Autoimmune diseasesFING000001316.19e-04
10699TNFRSF4/TNFRSF9 ratioGCST903159396.18e-04
10700RAB10 levelsGCST904704036.17e-04
10701FCRL1 levelsGCST904692056.14e-04
10702IGF1 levelsUKBB000003376.13e-04
10703DNAJA2/SCAMP3 ratioGCST903145076.12e-04
10704Doctor diagnosed hayfever or allergic rhinitis | Medical informationUKBB000001926.12e-04
10705LGALS3 levelsGCST900120096.09e-04
10706IDP dMRI TBSS MO Medial lemniscus RGCST900039606.06e-04
10707WFIKKN2 levelsGCST904221276.04e-04
10708SKAP2/VSIR ratioGCST903158496.03e-04
10709rfMRI amplitudes (ICA100 node 44)GCST900046326.02e-04
10710Asthma and allergyFING000001156.00e-04
10711Psoriasis (vulgaris), strict definitionFING000012235.98e-04
10712SAMD9L levelsGCST904705245.98e-04
10713TNFSF10 levelsGCST904709175.95e-04
10714CERT/MAX ratioGCST903140285.95e-04
10715Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T443ECGU0004435.94e-04
10716TNFSF10 levelsGCST900120115.93e-04
10717FHIT/PARK7 ratioGCST903148215.91e-04
10718PPM1F levelsGCST904702975.90e-04
10719Lysophosphatidylcholine (24:0) [sn1] levelsGCST900254255.90e-04
10720ESYT2 levelsGCST904691565.90e-04
10721CNST/PRKAR1A ratioGCST903141615.86e-04
10722Pollen allergyFING000011765.82e-04
10723Percentage of fucosylation of monogalactosylated structures in total neutral plasma glycans (GP74)GCST906685185.81e-04
10724Disorders of sclera, cornea, iris and ciliary bodyFING000004585.79e-04
10725MCFD2/VSIR ratioGCST903154115.77e-04
10726SERPINA7 levelsGCST904705875.75e-04
10727METAP1D/VASH1 ratioGCST903154295.73e-04
10728KIAA2013 levelsGCST904696795.71e-04
10729Lichen ruber planus, wide definition including periferal and oral lichen planusFING000007225.70e-04
10730IGLC2 levelsGCST904695365.70e-04
10731CD46/TNFRSF14 ratioGCST903138385.68e-04
10732Mean reticulocyte volume (UKB data field 30260)GCST904680885.68e-04
10733Coeliac diseaseFING000003125.68e-04
10734ATP5IF1/DECR1 ratioGCST903133825.65e-04
10735HippSubfield rh volume hippocampal-fissureGCST900026945.64e-04
10736TBL1X levelsGCST904708155.63e-04
10737DPEP2 levelsGCST904690315.61e-04
10738PARK7 levelsGCST904701595.58e-04
10739SDC4/SELP ratioGCST903158175.57e-04
10740Psoriasis (PheCode 696.4)GCST904761875.56e-04
10741CNTNAP4 levelsGCST904688095.56e-04
10742Psoriasis and related disorder (PheCode 696)GCST904761865.56e-04
10743NFKB1 levelsGCST904700375.55e-04
10744CRYBB1 levelsGCST904688745.55e-04
10745PRKAR1A/SNAP23 ratioGCST903157285.54e-04
10746Thyroid stimulating hormone levelsGCST903193215.54e-04
10747Selective deficiency of immunoglobulin G [IgG] subclassesFING000012885.52e-04
10748CD300C levelsGCST904686205.50e-04
10749Malignant neoplasm of brain, excluding all cancers (controls excluding all cancers)FING000007525.49e-04
10750EPS8L2/LGALS4 ratioGCST903146855.48e-04
10751ACYP1 levelsGCST904682145.47e-04
10752PDCD1 levelsGCST904701815.45e-04
10753Subclinical hypothyroidism in pregnancyGCST904351975.44e-04
10754CXCL10/CXCL11 ratioGCST903143305.43e-04
10755ESAM/FUT8 ratioGCST903147115.41e-04
10756severe traumatic brain injury, does not include concussionFING000013005.41e-04
10757CASP3/MESD ratioGCST903136365.40e-04
10758F-lentils/beans liking (derived food-liking factor)GCST900947935.38e-04
10759CLEC1B/LBR ratioGCST903140955.38e-04
10760First line medication for Crohn's diseaseFING000005445.37e-04
10761SPARC/ZBTB16 ratioGCST903158755.34e-04
10762Benign neoplasm of eye (PheCode 224)GCST904756265.34e-04
10763ESAM/TNFRSF14 ratioGCST903147205.30e-04
10764Actinic keratosisFING000000135.27e-04
10765CRADD/HSPA1A ratioGCST903142395.25e-04
10766AmygNuclei lh volume Medial-nucleusGCST900026535.24e-04
10767NBL1 levelsGCST904700015.22e-04
10768PRSS22 levelsGCST904703415.19e-04
10769Liver fatGCST905668175.19e-04
10770eosinophil (fraction, mean, inv-norm transformed)GCST904753005.18e-04
10771AARSD1/PIK3AP1 ratioGCST903131295.18e-04
10772Omega-3 fatty acids to total fatty acids percentageGCST905020905.17e-04
10773HBEGF levelsGCST902413925.14e-04
10774Other hammer toe(s) (acquired)FING000010545.12e-04
10775AXIN1/BACH1 ratioGCST903134005.09e-04
10776T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 5)GCST903205685.08e-04
10777FOLR3 levelsGCST904692615.07e-04
10778Sacroiliitis, not elsewhere classifiedFING000012735.07e-04
10779Prescriptions - albuterol | beta2-agonist,bronchodilator,asthmaUKBB000006585.06e-04
10780Prescriptions - beta2-agonist|bronchodilator|asthmaUKBB000006705.06e-04
10781TNFRSF13B/TNFSF13B ratioGCST903159335.06e-04
10782MMP10 levelsGCST900120505.06e-04
10783SMPD1/SMPDL3A ratioGCST903158545.06e-04
10784eosinophil (fraction, maximum, inv-norm transformed)GCST904752975.04e-04
10785PDGFB levelsGCST900120165.03e-04
10786Psoriasis vulgaris (PheCode 696.41)GCST904761905.01e-04
10787CDH6/NTRK2 ratioGCST903139625.01e-04
10788AmygNuclei rh volume Whole-amygdalaGCST900026675.00e-04
10789IGF2R/LGMN ratioGCST903151314.98e-04
10790Allergic rhinitisFING000000714.97e-04
10791CLEC4D/HGF ratioGCST903141104.97e-04
10792Acute upper respiratory infectionsFING000000344.95e-04
10793Glycated haemoglobin (HbA1c) | Blood biochemistryUKBB000002894.94e-04
10794Alkenylphosphatidylethanolamine (P-20:0/18:2) levelsGCST900256834.94e-04
10795HSD11B1 levelsGCST904694824.92e-04
10796Eosinophil percentage of white cellsGCST0046004.92e-04
10797NCR1 levelsGCST900901534.91e-04
10798ITGB1BP2 levelsGCST900120584.89e-04
10799Ceramide (d18:2/24:0) levelsGCST900240554.89e-04
10800DOK2/PPP1R2 ratioGCST903145374.89e-04
10801CCN2/ENO2 ratioGCST903137124.88e-04
10802VTI1A levelsGCST904710604.87e-04
10803Thyroxine levelsGCST902002934.87e-04
10804BTN2A1/SPINT2 ratioGCST903135504.86e-04
10805Second line medication for Crohn's diseaseFING000012844.85e-04
10806TGFB1 levelsGCST902748184.84e-04
10807CD69/SNAP23 ratioGCST903138864.83e-04
10808Takes medication for peripheral vascular disease?GCST904752204.83e-04
10809Hypothyroidism NOS (PheCode 244.4)GCST904756534.83e-04
10810ISM1 levelsGCST904696304.82e-04
10811Triglycerides to total lipids in chylomicrons and extremely large VLDL percentage (UKB data field 23583)GCST902696804.78e-04
10812Left-hemisphere control network to putamen white-matter structural connectivityGCST903027544.78e-04
10813Eosinophil percentage of granulocytesGCST0046174.78e-04
10814PEBP1 levelsGCST904702054.77e-04
10815LAT/PDGFA ratioGCST903152854.76e-04
10816PDCD1/TNFRSF8 ratioGCST903156104.76e-04
10817GFRA1/SPON2 ratioGCST903149234.75e-04
10818CPB1/REG1B ratioGCST903142134.75e-04
10819Inguinal hernia, bilateralFING000006824.74e-04
10820BCR levelsGCST904684364.74e-04
10821Right-hemisphere dorsal attention network to thalamus white-matter structural connectivityGCST903028064.73e-04
10822NAGPA levelsGCST904699964.73e-04
10823LUZP2 levelsGCST904698194.72e-04
10824Generalized epilepsyFING000005674.72e-04
10825GZMH levelsGCST904694254.72e-04
10826LAIR1 levelsGCST904697284.70e-04
10827SPINK1 levelsGCST904707214.68e-04
10828PLA2G4A/SDC4 ratioGCST903156684.68e-04
10829F-sauces liking (derived food-liking factor)GCST900948314.68e-04
10830GP6/TMSB10 ratioGCST903149754.68e-04
10831Angina pectoris | Ischaemic heart diseasesUKBB000000314.67e-04
10832Primary open angle glaucoma (PheCode 365.11)GCST904758754.66e-04
10833CREG1/GUSB ratioGCST903142494.65e-04
10834SCRG1 levelsGCST904705544.65e-04
10835DEFA1_DEFA1B/PTGDS ratioGCST903144554.64e-04
10836Benign neoplasm: RectumFING000001964.63e-04
10837Urinary ethanolamine to urinary creatinine ratioGCST904517174.60e-04
10838HayfeverGCST904681314.57e-04
10839Rheumatoid arthritisFING000012674.57e-04
10840HLAE/IL15 ratioGCST903150614.55e-04
10841Basal cell carcinomaGCST900134104.55e-04
10842Eosinophil countGCST0046064.55e-04
10843Left-hemisphere control network to amygdala white-matter structural connectivityGCST903027574.52e-04
10844TPSAB1 levelsGCST904709514.52e-04
10845C4BPB levelsGCST904684994.51e-04
10846CREG1/SMPDL3A ratioGCST903142524.50e-04
10847Biological Sibling: AsthmaGCST904763724.50e-04
10848PNMA1 levelsGCST904702764.50e-04
10849Treatment/medication code - ventolin 100micrograms inhaler | MedicationsUKBB000008604.49e-04
10850KIR2DL2 levelsGCST904696844.49e-04
10851CTSO/IGF2R ratioGCST903143174.48e-04
10852Retrobulbar neuritis in diseases classified elsewhereFING000012654.48e-04
10853IRAK1/NFATC1 ratioGCST903151944.48e-04
10854GZMA/GZMB ratioGCST903150074.47e-04
10855MAP4K5/TBCC ratioGCST903153854.47e-04
10856CTSF/SMPDL3A ratioGCST903143164.43e-04
10857CD300E/CD59 ratioGCST903137944.42e-04
10858Alkylphosphatidylcholine (O-34:1) levelsGCST900249254.41e-04
10859F11R/TMSB10 ratioGCST903147294.40e-04
10860Light-intensity physical activity durationGCST900614214.38e-04
10861Eosinophil countGCST900023814.38e-04
10862ANGPTL4 levelsGCST904683054.38e-04
10863ESM1 levelsGCST900120684.37e-04
10864Histidine levels (UKB data field 23463)GCST902695604.36e-04
10865NAGA levelsGCST904699944.36e-04
10866Biological Grandparent (maternal): Alzheimer's / Other DementiaGCST904754844.35e-04
10867Blood cell traits latent factor 17 (white cell)GCST905592594.35e-04
10868HippSubfield lh volume subiculum-headGCST900026714.34e-04
10869SCARA5/TGFBI ratioGCST903158094.33e-04
10870XG levelsGCST904710824.31e-04
10871PCDH17 levelsGCST904701694.25e-04
10872DTI autoptx MD unc r tractGCST903852464.25e-04
10873FOLR3/KLK8 ratioGCST903148684.24e-04
10874Eosinophil countGCST900022984.23e-04
10875Free cholesterol to total lipids in large VLDL percentage (UKB data field 23592)GCST902696894.23e-04
10876BTN2A1/IFNGR1 ratioGCST903135434.22e-04
10877ATP5IF1/FXN ratioGCST903133864.22e-04
10878TNIP1 levelsGCST904709254.21e-04
10879BTN2A1 levelsGCST904684804.20e-04
10880ITGB1/SELP ratioGCST903152304.20e-04
10881CXCL11 levelsGCST902747814.18e-04
10882Principal component-derived dietary pattern 52GCST901330564.18e-04
10883Phosphate | Blood biochemistryUKBB000006444.18e-04
10884DKK1 levelsGCST900120604.18e-04
10885PTH1R levelsGCST904703714.17e-04
10886SPON2 levelsGCST904707324.17e-04
10887CALCOCO1/PDLIM7 ratioGCST903136074.17e-04
10888FUS levelsGCST904692784.16e-04
10889FABP6 levelsGCST904691784.15e-04
10890CXCL5/SDC4 ratioGCST903143534.15e-04
10891Other haemoglobinopathiesFING000010534.15e-04
10892DDC levelsGCST904689674.13e-04
10893Primary biliary cholangitis (PBC)FING000012114.13e-04
10894TPM2 levelsGCST902431224.12e-04
10895SVEP1 levelsGCST902429284.11e-04
10896FAM3C levelsGCST904691874.10e-04
10897CD80 levelsGCST904686504.10e-04
10898OLR1/PLAUR ratioGCST903155844.08e-04
10899FABP2 levelsGCST904691744.08e-04
10900FURIN/PLA2G15 ratioGCST903148874.08e-04
10901Endometriosis ASRM stages 3,4FING000004984.08e-04
10902ZFYVE19 levelsGCST904710984.07e-04
10903CNST levelsGCST904688014.04e-04
10904Phosphatidylcholine levelsGCST900929374.04e-04
10905ADH1B levelsGCST904682434.04e-04
10906DIABLO/PRKAR1A ratioGCST903144694.01e-04
10907ENTPD5 levelsGCST904691214.01e-04
10908VASP levelsGCST904710284.00e-04
10909Tryptophan betaine levelsGCST901998194.00e-04
10910CD83/TNFRSF4 ratioGCST903139073.99e-04
10911EREG/HBEGF ratioGCST903147023.99e-04
10912INPP1 levelsGCST904696163.98e-04
10913RGMA/RGMB ratioGCST903157693.97e-04
10914F3/GFRA1 ratioGCST903147413.95e-04
10915TNFRSF11B levelsGCST902431583.94e-04
10916CST6/GAL ratioGCST903143023.94e-04
10917Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T447ECGU0004473.94e-04
10918ARHGAP1 levelsGCST904683523.91e-04
10919Rheumatoid arthritis and other inflammatory (PheCode 714)GCST904762283.90e-04
10920CEP43 levelsGCST904687153.89e-04
10921Spondylosis without myelopathy (PheCode 721.1)GCST904762363.89e-04
10922CCN3 levelsGCST902424923.89e-04
10923eosinophil (fraction, minimum, inv-norm transformed)GCST904753033.87e-04
10924Other contact dermatitisFING000009903.85e-04
10925MDH1 levelsGCST904698763.85e-04
10926Other disorders of fluid, electrolyte and acid-base balanceFING000010273.82e-04
10927CFI levelsGCST902407823.81e-04
10928TNFRSF1A/TNFRSF1B ratioGCST903159373.80e-04
10929HyperthyroidismGCST904681363.79e-04
10930VPS37A levelsGCST904710463.78e-04
10931EGFR/MEGF9 ratioGCST903146143.78e-04
10932CX3CL1/DSG2 ratioGCST903143233.77e-04
10933DAAM1 levelsGCST904689413.77e-04
10934PLIN3/VSIR ratioGCST903156793.75e-04
10935Mineral and other dietary supplements - None of the above | MedicationUKBB000004743.74e-04
10936Triglyceride levels in large HDLGCST900928543.70e-04
10937XIAP levelsGCST904710833.70e-04
10938Fasting blood glucoseGCST0005683.70e-04
10939ATOX1/SPARC ratioGCST903133753.69e-04
10940Abdominal subcutaneous adipose tissue normalizedGCST902673483.69e-04
10941eosinophil (absolute count, minimum, inv-norm transformed)GCST904752943.67e-04
10942SUSD4 levelsGCST904707883.66e-04
10943EREG/MPI ratioGCST903147053.66e-04
10944GRAP2/TYMP ratioGCST903149903.65e-04
10945DAG1/GP6 ratioGCST903143753.64e-04
10946EPHB6/TNFRSF9 ratioGCST903146823.64e-04
10947Carnitine levelsGCST902399913.61e-04
10948Plasma argininate* levels in chronic kidney diseaseGCST902648263.61e-04
10949Mean reticulocyte volumeGCST900023963.61e-04
10950MTSS2 levelsGCST904699613.60e-04
10951ITGB1/VASN ratioGCST903152323.58e-04
10952CPXM1/VEGFC ratioGCST903142233.57e-04
10953Other acute lower respiratory infectionsFING000009213.57e-04
10954Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T444ECGU0004443.57e-04
10955LYN/TACC3 ratioGCST903153503.55e-04
10956ERBB2/PTPRF ratioGCST903146883.54e-04
10957ALCAM/LRRC25 ratioGCST903132393.54e-04
10958HTRA2 levelsGCST904694943.53e-04
10959GMPR2 levelsGCST904693673.53e-04
10960C21orf58 levelsGCST906183803.52e-04
10961FCRL1/TCL1A ratioGCST903147953.51e-04
10962CST3 levelsGCST904688943.50e-04
10963Urine X-24798 levels in chronic kidney diseaseGCST902668023.50e-04
10964Mean sphered cell volume (UKB data field 30270)GCST904680893.48e-04
10965PDGFA/USP8 ratioGCST903156213.48e-04
10966RNASE6 levelsGCST904704793.47e-04
10967Non-cancer illness code, self-reported - hayfever/allergic rhinitis | Medical conditionsUKBB000005133.47e-04
10968Seropositive rheumatoid arthritis, wideFING000012983.46e-04
10969CASP8/DDX58 ratioGCST903136513.46e-04
10970RNASE1 levelsGCST904704763.45e-04
10971GP1BB levelsGCST904693813.45e-04
10972TNFRSF9 levelsGCST904709163.45e-04
10973Seborrhoeic dermatitisFING000012823.45e-04
10974Phosphoglycerides levelsGCST904992653.44e-04
10975Type 1 diabetesGCST900137913.43e-04
10976IFI30 levelsGCST904695093.43e-04
10977LRIG3 levelsGCST904697953.43e-04
10978CRACR2A/IRAG2 ratioGCST903142273.42e-04
10979AIDA levelsGCST904682653.40e-04
10980Eosinophill count | Blood countUKBB000002063.39e-04
10981In your lifetime, have you smoked a total of at least 100 cigarettes?GCST904763873.38e-04
10982Cutaneous abscess, furuncle and carbuncleFING000003733.37e-04
10983CCL5/TACC3 ratioGCST903137073.34e-04
10984LRRFIP1 levelsGCST904698053.33e-04
10985CD58/IL10RB ratioGCST903138503.33e-04
10986STK24 levelsGCST904707663.33e-04
10987EGF/MANF ratioGCST903146093.33e-04
10988TARBP2 levelsGCST904708053.32e-04
10989VCAM1 levelsGCST902433173.32e-04
10990DECR1 levelsGCST904689783.29e-04
10991DRG2/SEMA4D ratioGCST903145543.29e-04
10992ARHGAP25 levelsGCST902426513.27e-04
10993Ever had period extreme irritability | ManiaUKBB000002173.26e-04
10994NUDT5/SERPINB1 ratioGCST903155813.26e-04
10995LRCH4 levelsGCST904697913.25e-04
10996IL2RA/NCR1 ratioGCST903151613.24e-04
10997Atopic dermatitisFING000001253.24e-04
10998Bread intake | DietUKBB000001053.23e-04
10999IDP SWI T2star left putamenGCST900038673.22e-04
11000T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 60)GCST903208793.21e-04